bicalutamide
Selected indexed studies
- Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. (Lancet Oncol, 2022) [PMID:36075260]
- Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know. (J Cosmet Dermatol, 2022) [PMID:35032336]
- Bicalutamide: clinical pharmacokinetics and metabolism. (Clin Pharmacokinet, 2004) [PMID:15509184]
_Worker-drafted node — pending editorial review._
Connections
bicalutamide is a side effect of
Sources
- Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. (2022) pubmed
- Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know. (2022) pubmed
- Bicalutamide: clinical pharmacokinetics and metabolism. (2004) pubmed
- [Bicalutamide]. (2000) pubmed
- Bicalutamide dosages used in the treatment of prostate cancer. (1999) pubmed
- Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials. (2025) pubmed
- Bicalutamide in advanced prostate cancer. A review. (1998) pubmed
- Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative. (2022) pubmed
- Bicalutamide: in early-stage prostate cancer. (2002) pubmed
- Bicalutamide (Casodex) in the treatment of prostate cancer. (2004) pubmed